Hank Mansbach has been appointed chief medical officer of 89bio. Mansbach comes to the biotech startup from Ultragenyx (NASDAQ: [[ticker:RARE]]), where he was head of metabolic and neurology global clinical development. 89bio, which splits its operations between San Francisco and Herzliya, Israel, raised $60 million in financing last October to support its development of a drug for nonalcoholic steatohepatitis that it acquired from Teva Pharmaceutical (NYSE: [[ticker:TEVA]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
